Metacrine lays off half its staff, mainly researchers, and ditches more work to focus on IBD after NASH disasternews2022-02-11T14:27:13+00:00February 11th, 2022|FierceBiotech|
Hunting for cutting-edge biotech, Fujifilm sets up early-stage VC fundnews2022-02-11T10:43:34+00:00February 11th, 2022|FierceBiotech|
With approval in sight, ObsEva sells regional rights to women’s health drug for tiny upfrontnews2022-02-11T09:50:40+00:00February 11th, 2022|FierceBiotech|
Vivocore combines InterVivo, Transpharmation to form neuroscience CRO with an interest in psilocybinnews2022-02-10T19:40:49+00:00February 10th, 2022|FierceBiotech|
Curevo will go head-to-head against GSK’s Shingrix thanks to new $60M financingnews2022-02-10T16:38:01+00:00February 10th, 2022|FierceBiotech|
FDA denies Ardelyx’s appeal against kidney drug rejection, hammering another nail in tenapanor’s coffinnews2022-02-10T13:13:39+00:00February 10th, 2022|FierceBiotech|
AstraZeneca dumps late-phase, next-gen COVID-19 vaccine, calling time on a beta player in an omicron worldnews2022-02-10T10:29:04+00:00February 10th, 2022|FierceBiotech|
Indapta snags $50M financing and signs on former Juno exec as CEOnews2022-02-09T19:51:25+00:00February 9th, 2022|FierceBiotech|
Engineered TCR-T cells by Fred Hutch, San Raffaele-Intellia fend off evasive leukemia, solid tumorsnews2022-02-09T16:41:30+00:00February 9th, 2022|FierceBiotech|
Checkmate plucks BMS exec Bash to be new CEOnews2022-02-09T15:12:28+00:00February 9th, 2022|FierceBiotech|
